About PeopleBio R&D
PeopleBio R&D is a company based in Seongnam-si (South Korea) founded in 2002. The company has 60 employees. PeopleBio R&D operates in a competitive market with competitors including Cytox, ADx NeuroSciences, Amprion, Durin Technologies and Adlyfe, among others.
- Headquarter Seongnam-si, South Korea
- Employees 60
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website peoplebio.net
- Legal Name Peoplebio. Inc.
- Annual Revenue$1.97 M (USD)12.64as on Dec 31, 2025
- Net Profit-$10.88 M (USD)-43.99as on Dec 31, 2025
- EBITDA-$4.87 M (USD)5.8as on Dec 31, 2025
- Employee Count60
IPO & Listings of PeopleBio R&D
PeopleBio R&D is a publicly listed company on the KRX with ticker symbol 304840 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date19 Oct 2020
- Listed onKRX: 304840
- Listed entityPeopleBio. Inc.
- Exchange sectorHealth technology
- ISINKR7304840002
- Share price1,234.00 KRW (-4.27% on the day) · 2026-05-11
- Market capitalisation30,184,244,780.00 KRW
- EPS (diluted, trailing year)-735.26 KRW
- Volume (last session)165,742
- Analyst consensusNo rating
Financials of PeopleBio R&D
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 2.85B KRW | -15.71B KRW | -7.04B KRW |
| 2024 | 2.53B KRW | -10.91B KRW | -7.47B KRW |
| 2023 | 4.45B KRW | -16.03B KRW | -13.68B KRW |
| 2022 | 4.44B KRW | -14.30B KRW | -10.42B KRW |
| 2021 | 577.1M KRW | -4.70B KRW | -6.50B KRW |
Detailed financial statements for PeopleBio R&D
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of PeopleBio R&D
PeopleBio R&D operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cytox, ADx NeuroSciences, Amprion, Durin Technologies and Adlyfe, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cytoxgroup.com | 2007 | Oxford, United Kingdom | $12.13M | 12 | Prognostic tests for assessing dementia risk are developed. | |
| adxneurosciences.com | 2011 | Ghent, Belgium | $3.17M | 14 | Biomarker assays for neurodegenerative diseases are developed using custom antibodies. | |
| ampriondx.com | 2006 | Houston, United States | $11.76M | 34 | Assay technology for misfolded proteins in neurodegenerative disorders is developed. | |
| durintechnologies.com | 2010 | Camden, United States | $8.05M | – | Developer of the diagnostic test for neurodegenerative diseases | |
| adlyfe.com | 2003 | Rockville, United States | $8.3M | 1 | Develops biomarkers and diagnostic tests for amyloid-related diseases. | |
| alseres.com | 1972 | Auburndale, United States | $4M | 3 | Therapeutic and diagnostic products for CNS disorders are developed. | |
| nippontect.co.jp | 2015 | Minato, Japan | – | – | AI and cloud-based solutions for dementia diagnosis are provided. |
Detailed competitors of PeopleBio RD
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of PeopleBio R&D
The website of PeopleBio R&D (peoplebio.net) receives about 1.2K visits a month.
- Monthly visits1.2K
▼ 75.1% vs previous month
Latest news on Peoplebio R&D
Complete news archive for PeopleBio RD
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to PeopleBio R&D
10 companies that operate in the same segment as PeopleBio R&D (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about PeopleBio R&D
PeopleBio R&D was founded in 2002.
PeopleBio R&D is headquartered in Seongnam-si, South Korea. It is registered at Seongnam-si, Gyeonggi-do, South Korea.
PeopleBio R&D has 60 employees.
Annual revenue of PeopleBio R&D is $1.97M as on Dec 31, 2025.
PeopleBio RD was founded in 2002 in Seongnam-si, South Korea, as a molecular diagnostics firm. Focus is placed on immunoassays for detecting neurodegenerative conditions like Alzheimers and Parkinsons. The Multimer Detection System platform is utilized, involving sandwich ELISA tests with capturing and detection antibodies to identify protein multimers in CSF, plasma, exosomes, and body fluids. Tests are also created for therapeutic antibodies and spongiform encephalopathies.
PeopleBio R&D's top competitors include Amprion, ADx NeuroSciences and Cytox.
Yes, PeopleBio R&D is publicly traded on KRX under the ticker symbol 304840.